Telix Pharmaceuticals Limited
TLX
$9.08
-$0.28-2.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -115.08% | -109.70% | 3.75% | 6.17% | 295.18% |
| Total Depreciation and Amortization | 200.98% | 472.92% | 21.70% | 24.55% | 17.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.16% | 157.72% | 107.25% | 112.10% | 7.52% |
| Change in Net Operating Assets | -- | -- | -91.80% | -96.28% | -- |
| Cash from Operations | -54.91% | 146.61% | -62.85% | -61.98% | 172.53% |
| Capital Expenditure | -125.41% | -113.01% | -44.40% | -47.78% | -61.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -637.46% | -- | -612.93% | -629.58% | -19,044.04% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -51.41% | -162.04% | -376.30% | -387.42% | -- |
| Cash from Investing | -428.60% | -2,108.35% | -295.18% | -304.41% | -2,832.32% |
| Total Debt Issued | -- | -- | 19,864.49% | 19,864.49% | -3.28% |
| Total Debt Repaid | -128.65% | -- | -28.99% | -28.99% | -99.75% |
| Issuance of Common Stock | 8.61% | 107.36% | -90.20% | -90.20% | -85.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -160.91% | -51.70% | 11,508.06% | 11,779.46% | 28.33% |
| Foreign Exchange rate Adjustments | 321.34% | 94.33% | 2,106.88% | 2,153.78% | -90.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,260.96% | -33,364.07% | 7,064.59% | 7,227.32% | -171.15% |